Targeting Sphingosine-1-phosphate for Cancer Therapy

Overview

Journal Br J Cancer

Specialty Oncology

Date 2006 Oct 7

PMID 17024123

Citations 28

Authors

R A Sabbadini

Affiliations

Soon will be listed here.

Abstract

This review summarises some important new findings that implicate sphingosine-1-phosphate (S1P) as a potent tumorigenic and angiogenic agent released from cancerous tumours into the tumour microenvironment. Also explored is the novel concept that bioactive lipid signalling molecules, like S1P, can themselves be targets for rational drug design, thereby opening up an entire class of lipidomic-based therapeutics for oncology and other human diseases.

Citing Articles

Making a difference.

Sabbadini R Eur J Transl Myol. 2024; 34(3).

PMID: 39105478 PMC: 11487635. DOI: 10.4081/ejtm.2024.12811.

Hypogelsolinemia and Decrease in Blood Plasma Sphingosine-1-Phosphate in Patients Diagnosed with Severe Acute Pancreatitis.

Wollny T, Watek M, Wnorowska U, Piktel E, Gozdz S, Kurek K Dig Dis Sci. 2021; 67(2):536-545.

PMID: 33620599 PMC: 8885474. DOI: 10.1007/s10620-021-06865-y.

S1PR1 as a Novel Promising Therapeutic Target in Cancer Therapy.

Rostami N, Nikkhoo A, Ajjoolabady A, Azizi G, Hojjat-Farsangi M, Ghalamfarsa G Mol Diagn Ther. 2019; 23(4):467-487.

PMID: 31115798 DOI: 10.1007/s40291-019-00401-5.

Unexpected profile of sphingolipid contents in blood and bone marrow plasma collected from patients diagnosed with acute myeloid leukemia.

Watek M, Durnas B, Wollny T, Pasiarski M, Gozdz S, Marzec M Lipids Health Dis. 2017; 16(1):235.

PMID: 29216917 PMC: 5721620. DOI: 10.1186/s12944-017-0624-1.

Sphingosine-1-Phosphate Metabolism and Its Role in the Development of Inflammatory Bowel Disease.

Wollny T, Watek M, Durnas B, Niemirowicz K, Piktel E, Zendzian-Piotrowska M Int J Mol Sci. 2017; 18(4).

PMID: 28362332 PMC: 5412326. DOI: 10.3390/ijms18040741.

References

Maceyka M, Milstien S, Spiegel S . Sphingosine kinases, sphingosine-1-phosphate and sphingolipidomics. Prostaglandins Other Lipid Mediat. 2005; 77(1-4):15-22. DOI: 10.1016/j.prostaglandins.2004.09.010. View

French K, Schrecengost R, Lee B, Zhuang Y, Smith S, Eberly J . Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res. 2003; 63(18):5962-9. View

Dvorak H . Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med. 1986; 315(26):1650-9. DOI: 10.1056/NEJM198612253152606. View

Igarashi J, Erwin P, Dantas A, Chen H, Michel T . VEGF induces S1P1 receptors in endothelial cells: Implications for cross-talk between sphingolipid and growth factor receptors. Proc Natl Acad Sci U S A. 2003; 100(19):10664-9. PMC: 196861. DOI: 10.1073/pnas.1934494100. View

Lee O, Kim Y, Lee Y, Moon E, Lee D, Kim J . Sphingosine 1-phosphate induces angiogenesis: its angiogenic action and signaling mechanism in human umbilical vein endothelial cells. Biochem Biophys Res Commun. 1999; 264(3):743-50. DOI: 10.1006/bbrc.1999.1586. View

Goparaju S, Jolly P, Watterson K, Bektas M, Alvarez S, Sarkar S . The S1P2 receptor negatively regulates platelet-derived growth factor-induced motility and proliferation. Mol Cell Biol. 2005; 25(10):4237-49. PMC: 1087716. DOI: 10.1128/MCB.25.10.4237-4249.2005. View

Kawamori T, Osta W, Johnson K, Pettus B, Bielawski J, Tanaka T . Sphingosine kinase 1 is up-regulated in colon carcinogenesis. FASEB J. 2005; 20(2):386-8. DOI: 10.1096/fj.05-4331fje. View

Milstien S, Spiegel S . Targeting sphingosine-1-phosphate: a novel avenue for cancer therapeutics. Cancer Cell. 2006; 9(3):148-50. DOI: 10.1016/j.ccr.2006.02.025. View

Pchejetski D, Golzio M, Bonhoure E, Calvet C, Doumerc N, Garcia V . Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models. Cancer Res. 2005; 65(24):11667-75. DOI: 10.1158/0008-5472.CAN-05-2702. View

10.

Murata N, Sato K, Kon J, Tomura H, Okajima F . Quantitative measurement of sphingosine 1-phosphate by radioreceptor-binding assay. Anal Biochem. 2000; 282(1):115-20. DOI: 10.1006/abio.2000.4580. View

11.

Bektas M, Payne S, Liu H, Goparaju S, Milstien S, Spiegel S . A novel acylglycerol kinase that produces lysophosphatidic acid modulates cross talk with EGFR in prostate cancer cells. J Cell Biol. 2005; 169(5):801-11. PMC: 2171605. DOI: 10.1083/jcb.200407123. View

12.

Argraves K, Wilkerson B, Argraves W, Fleming P, Obeid L, Drake C . Sphingosine-1-phosphate signaling promotes critical migratory events in vasculogenesis. J Biol Chem. 2004; 279(48):50580-90. DOI: 10.1074/jbc.M404432200. View

13.

Maceyka M, Sankala H, Hait N, Le Stunff H, Liu H, Toman R . SphK1 and SphK2, sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism. J Biol Chem. 2005; 280(44):37118-29. DOI: 10.1074/jbc.M502207200. View

14.

Wenk M . The emerging field of lipidomics. Nat Rev Drug Discov. 2005; 4(7):594-610. DOI: 10.1038/nrd1776. View

15.

Visentin B, Vekich J, Sibbald B, Cavalli A, Moreno K, Matteo R . Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell. 2006; 9(3):225-38. DOI: 10.1016/j.ccr.2006.02.023. View

16.

Cuvillier O, Levade T . Enzymes of sphingosine metabolism as potential pharmacological targets for therapeutic intervention in cancer. Pharmacol Res. 2003; 47(5):439-45. DOI: 10.1016/s1043-6618(03)00053-7. View

17.

Hla T . Physiological and pathological actions of sphingosine 1-phosphate. Semin Cell Dev Biol. 2004; 15(5):513-20. DOI: 10.1016/j.semcdb.2004.05.002. View

18.

Vadas M, Gamble J . Endothelial adhesion molecules in atherogenesis. A concerto or a solo?. Circ Res. 1996; 79(6):1216-7. DOI: 10.1161/01.res.79.6.1216. View

19.

Liu Y, Wada R, Yamashita T, Mi Y, Deng C, Hobson J . Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J Clin Invest. 2000; 106(8):951-61. PMC: 314347. DOI: 10.1172/JCI10905. View

20.

Spiegel S, Milstien S . Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol. 2003; 4(5):397-407. DOI: 10.1038/nrm1103. View